EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Hidden Risks of Medication Underuse in Migraine Progression

Heui-Soo Moon, Pil-Wook Chung

Headache and Pain Research · 31.10.2025 · 26 (3) · 209-217

DOI: 10.62087/hpr.2025.0019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache and Pain Research, erschienen am 31.10.2025. Verfasst von Heui-Soo Moon und 1 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Migraine is a progressive neurological disorder in which inadequate treatment can lead to chronification. For decades, clinical attention has centered on medication overuse headache (MOH) as the primary iatrogenic risk factor for this progression. However, medication underuse (MU) has emerged as a critical yet less established framework for understanding gaps in migraine care. This review reframes MU, which includes ineffective therapies, delayed administration, and non-adherence due to intolerability, as an active contributor to disease progression. Untreated or undertreated migraine attacks promote the development of central sensitization, a state of neuronal hyperexcitability that increases attack frequency, severity, and treatment resistance. This paper posits that MU and MOH are not opposing concepts but interconnected manifestations of suboptimal disease management. Specifically, disease progression driven by MU can directly precipitate the escalating medication use that characterizes MOH, resulting in a more refractory clinical state. Therefore, preventing chronification requires a paradigm shift from merely avoiding overuse to achieving optimal use. This entails adherence to evidence-based guidelines for both acute and preventive therapy—implementing stratified acute care within the neurobiological window to prevent central sensitization and initiating timely preventive treatment in eligible patients to reduce the overall attack burden. The integration of novel targeted therapies provides new opportunities to overcome the limitations of traditional agents. Ultimately, reducing the risks associated with MU through proactive, evidence-based management and strong patient–clinician communication is essential to alter the natural history of migraine and prevent the long-term disability associated with its progression.

Zitieren

APA

Moon, H., & Chung, P. (2025). The Hidden Risks of Medication Underuse in Migraine Progression. Headache and Pain Research, 26(3), 209-217. https://doi.org/10.62087/hpr.2025.0019

Vancouver

Moon H, Chung P. The Hidden Risks of Medication Underuse in Migraine Progression. Headache and Pain Research. 2025;26(3):209-217. doi:10.62087/hpr.2025.0019

BibTeX
@article{Moon2025,
  author = {Moon, Heui-Soo and Chung, Pil-Wook},
  title = {The Hidden Risks of Medication Underuse in Migraine Progression},
  journal = {Headache and Pain Research},
  year = {2025},
  volume = {26},
  number = {3},
  pages = {209--217},
  doi = {10.62087/hpr.2025.0019}
}
Kostenlos starten →